Table 2 Association between the clinicopathological features of suspected hereditary breast cancer and the pathogenic or likely pathogenic variants of non-BRCA cancer predisposition genes (n = 120 patients)
Clinicopathological features | High-penetrance mutations | Moderate-penetrance mutations | None or VUS | |||||
|---|---|---|---|---|---|---|---|---|
Number ofpatients | % | Number ofpatients | % | Number ofpatients | % | p-value | ||
Breast cancer site | ||||||||
Bilateral | 2 | 18.2 | 0 | 0 | 9 | 81.8 | 0.106* | |
Unilateral | 3 | 2.8 | 4 | 3.7 | 102 | 93.5 | ||
Breast cancer subtype (n = 117, excluding patients with unknown breast cancer subtypes) | ||||||||
TNBC | 0 | 0 | 1 | 4.5 | 21 | 95.5 | >0.99* | |
hormone + and/or HER2+ | 4 | 4.2 | 3 | 3.2 | 88 | 92.6 | ||
Concomitant diagnosis with ovarian cancer | ||||||||
Yes | 0 | 0 | 0 | 0 | 3 | 100 | >0.99* | |
No | 5 | 4.3 | 4 | 3.4 | 108 | 92.3 | ||
Age at first diagnosis of breast cancer | ||||||||
< 35 years | 4 | 21.1 | 0 | 0 | 15 | 78.9 | 0.003* | |
≥ 35 years | 1 | 1.0 | 4 | 4.0 | 96 | 95.0 | ||
Family history of young (< 50 years old at diagnosis) breast and/or ovarian cancer patients within 2nd degree family | ||||||||
Yes | 2 | 6.3 | 3 | 9.4 | 27 | 84.3 | 0.053* | |
No | 3 | 3.4 | 1 | 1.1 | 84 | 95.5 | ||